 Connection
Yuki Fujiwara to Programmed Cell Death 1 Receptor
This is a "connection" page, showing publications Yuki Fujiwara has written about Programmed Cell Death 1 Receptor.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.457 |
|
|
|
-
Sonokawa T, Fujiwara Y, Pan C, Komohara Y, Usuda J. Enhanced systemic antitumor efficacy of PD-1/PD-L1 blockade with immunological response induced by photodynamic therapy. Thorac Cancer. 2024 06; 15(18):1429-1436.
Score: 0.177
-
Tsukamoto H, Komohara Y, Tomita Y, Miura Y, Motoshima T, Imamura K, Kimura T, Ikeda T, Fujiwara Y, Yano H, Kamba T, Sakagami T, Oshiumi H. Aging-associated and CD4 T-cell-dependent ectopic CXCL13 activation predisposes to anti-PD-1 therapy-induced adverse events. Proc Natl Acad Sci U S A. 2022 07 19; 119(29):e2205378119.
Score: 0.156
-
Yokoi M, Murakami K, Yaguchi T, Chamoto K, Ozasa H, Yoshida H, Shirakashi M, Ito K, Komohara Y, Fujiwara Y, Yano H, Ogimoto T, Hira D, Terada T, Hirai T, Tsukamoto H. ICOS+CD4+ T cells define a high susceptibility to anti-PD-1 therapy-induced lung pathogenesis. JCI Insight. 2025 05 22; 10(10).
Score: 0.047
-
Saito Y, Fujiwara Y, Shinchi Y, Mito R, Miura Y, Yamaguchi T, Ikeda K, Urakami S, Nakashima Y, Sakagami T, Suzuki M, Tabata Y, Komohara Y. Classification of PD-L1 expression in various cancers and macrophages based on immunohistocytological analysis. Cancer Sci. 2022 Sep; 113(9):3255-3266.
Score: 0.039
-
Shinchi Y, Ishizuka S, Komohara Y, Matsubara E, Mito R, Pan C, Yoshii D, Yonemitsu K, Fujiwara Y, Ikeda K, Tamada K, Sakagami T, Suzuki M. The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma. Cancer Immunol Immunother. 2022 Nov; 71(11):2645-2661.
Score: 0.038
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|